|
🐜
|
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
15 auth.
S. Gadgeel,
Solange Peters,
T. Mok,
A. Shaw,
Dong-Wan Kim,
S. Ou,
M. Pérol,
A. Wrona,
S. Novello,
R. Rosell,
...
A. Zeaiter,
Ting Liu,
E. Nüesch,
B. Balas,
D. Camidge
|
7 |
2018 |
7
🐜
|
|
🐜
|
PD-1 Blockade in Anaplastic Thyroid Carcinoma
24 auth.
J. Capdevila,
L. Wirth,
T. Ernst,
S. Ponce Aix,
Chia‐Chi Lin,
R. Ramlau,
M. Butler,
J. Delord,
H. Gelderblom,
P. Ascierto,
...
A. Fasolo,
D. Führer,
M. Hütter-Krönke,
P. Forde,
A. Wrona,
A. Santoro,
P. Sadow,
S. Szpakowski,
Hongqian Wu,
G. Bostel,
J. Faris,
S. Cameron,
A. Varga,
Matthew H. Taylor
|
7 |
2020 |
7
🐜
|
|
🐢
|
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
19 auth.
B. Cho,
Dong-Wan Kim,
A. Bearz,
S. Laurie,
M. McKeage,
G. Borra,
Keunchil Park,
Sang-We Kim,
M. Ghosn,
A. Ardizzoni,
...
E. Maiello,
A. Greystoke,
R. Yu,
K. Osborne,
W. Gu,
J. Scott,
V. Passos,
Yvonne Y. Lau,
A. Wrona
|
7 |
2017 |
7
🐢
|
|
🐜
|
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer
8 auth.
R. Dziadziuszko,
A. Le,
A. Wrona,
J. Jassem,
R. Camidge,
M. Varella-Garcia,
...
D. Aisner,
R. Doebele
|
6 |
2016 |
6
🐜
|
|
🐜
|
Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
82 auth.
I. Letovanec,
S. Finn,
P. Zygoura,
P. Smyth,
A. Soltermann,
L. Bubendorf,
E. Speel,
A. Marchetti,
D. Nonaka,
K. Monkhorst,
H. Hager,
M. Martorell,
A. Sejda,
R. Cheney,
J. Hernández-Losa,
...
E. Verbeken,
W. Weder,
S. Savic,
A. di Lorito,
A. Navarro,
E. Felip,
A. Warth,
P. Baas,
P. Meldgaard,
F. Blackhall,
A. Dingemans,
H. Dienemann,
R. Dziadziuszko,
J. Vansteenkiste,
C. O'Brien,
T. Geiger,
J. Sherlock,
J. Schageman,
U. Dafni,
R. Kammler,
K. Kerr,
E. Thunnissen,
R. Stahel,
S. Peters,
R. Stahel,
R. Rosell,
K. Kerr,
M. Molina,
A. Hiltbrunner,
N. Marti,
Z. Tsourti,
V. Polydoropoulou,
C. O'Brien,
S. Gray,
I. Opitz,
A. Curioni,
D. Lardinois,
E. Speel,
A. Ruland,
G. De Luca,
S. Malatesta,
A. Quinn,
L. Franklin,
W. Biernat,
A. Wrona,
W. Rzyman,
J. Jassem,
L. Madsen,
C. Camps,
E. Jantus-Lewintre,
R. Guijarro,
M. Nicolson,
D. Stevenson,
W. Mathieson,
J. de Jong,
E. Smit,
C. van Setten,
J. D. de Langen,
I. Sansano,
M. Pine,
M. Reid,
Elizabeth Taylor,
K. Nackaerts,
C. Dooms,
E. Wauters,
S. Van Der Borght,
T. Muley
|
6 |
2017 |
6
🐜
|
|
🐬
|
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
G. Sławiński,
A. Wrona,
A. Dąbrowska-Kugacka,
G. Raczak,
E. Lewicka
|
5 |
2020 |
5
🐬
|
|
🦁
|
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
A. Wrona,
R. Dziadziuszko,
J. Jassem
|
5 |
2018 |
5
🦁
|
|
🐜
|
Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters
20 auth.
S. Peters,
W. Weder,
U. Dafni,
K. Kerr,
L. Bubendorf,
P. Meldgaard,
K. O'Byrne,
A. Wrona,
J. Vansteenkiste,
E. Felip,
...
A. Marchetti,
S. Savic,
Shun Lu,
E. Smit,
A. Dingemans,
F. Blackhall,
P. Baas,
C. Camps,
R. Rosell,
R. Stahel
|
5 |
2014 |
5
🐜
|
|
🐜
|
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
42 auth.
K. Kerr,
U. Dafni,
K. Schulze,
E. Thunnissen,
L. Bubendorf,
H. Hager,
S. Finn,
W. Biernat,
L. Vliegen,
J. H. Losa,
A. Marchetti,
R. Cheney,
Arne Warth,
E. Speel,
F. Blackhall,
...
K. Monkhorst,
E. J. Lewintre,
Tischler,
C. Clark,
J. Bertran-Alamillo,
P. Meldgaard,
K. Gately,
A. Wrona,
P. Vandenberghe,
E. Felip,
G. D. Luca,
S. Savic,
T. Muley,
E. Smit,
A. Dingemans,
L. Priest,
P. Baas,
C. Camps,
W. Weder,
Polydoropoulou,
Thomas Geiger,
R. Kammler,
T. Sumiyoshi,
M. Molina,
D. Shames,
R. Stahel,
S. Peters
|
5 |
2018 |
5
🐜
|
